Matthew J O'Connell, PhD Email Matthew O'Connell
- SENIOR ASSOCIATE DEAN FOR CURRICULUM, RECRUITMENT AND ADMISSIONS | Graduate School of Biomedical Sciences
- PROFESSOR | Oncological Sciences
Cancer, Cancer Genetics, Cell Biology, Cell Cycle, Cell Division, Chromatin, DNA Recombination, DNA Repair, DNA Replication, Gene Discovery, Gene Regulation, Genetics, Genomics, Mitosis, Molecular Biology, Phosphorylation, Protein Kinases
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Development, Regeneration, and Stem Cells [DRS], Genetics and Data Science [GDS]
PhD, University of Adelaide
, UMDNJ-Robert Wood Johnson Medical School
, University of Oxford
, Imperial Cancer Research Fund
Edward J. Ronin Award
Graduate School of Biomedical Sciences, ISMMS
Outstanding Teaching by a Faculty Award, Graduate School of Biological Sciences
Mount Sinai School of Medicine
Excellence in Teaching Award, Institute of Medical Education
Mount Sinai School of Medicine
Scholar of the Leukemia and Lymphoma Society
Special Fellowship of the Leukemia Society of America
Australian Postgraduate Priority Research Award
Commonwealth Postgraduate Research Award
Fisher Scholarship in Honors Genetics
University of Adelaide
R. A. Fisher Prize in Genetics
University of Adelaide
Specific Clinical/Research Interest: Regulation of the cell cycle; control over genomic stability and chromosome dynamics; the design of novel strategies for anti-cancer therapies
Current Students: Kevin Barnum and Nagma Shah
Postdoctoral Fellows: Claudia Tapia-Alveal, Su-Jiun Lin
Research Associate: Cara Reynolds, Aaron Yeoh
Summary of Research Studies:
Perhaps the most fundamental process in biology is that by which one cell becomes two. Our research focuses on two related aspects of the biology that controls the integrity of the genome.
1. We study the control of the cell division cycle, and the signaling pathways (checkpoints) that respond to chromosomal damage and prevent cell cycle progression until that damage is repaired.
DNA damage checkpoints function throughout the cell cycle. Those working in G1 phase to prevent the replication of damaged DNA are almost invariably mutated or inactivated in cancers. These defects contribute not only to the instability of tumor cell genomes, but can also knock-out pro-apoptotic pathways, rendering tumors resistant to treatment. Those functioning in G2 phase to prevent commitment to mitosis are, however, virtually always intact and appear to be required for the viability of tumor cells that lack G1 checkpoints. Our research is geared to dissect the molecular and cell biology of G2 checkpoints, and aims to use this knowledge in the design and testing of targeted anti-cancer therapies. Taking genetic and genomic approaches, we utilize fission yeast as a gene and pathway discovery tool, and then apply this information to studies in human cells. We are currently focusing our efforts into: (1) the regulation and function of a checkpoint effector protein kinase, Chk1, informing its suitability as a target in anti-cancer therapy; and (2) the initiating events that modify lesions in DNA into structures that signal the checkpoint and can be repaired.
2. We are investigating how determinants of chromosome structure regulate chromosome segregation and DNA repair, with an emphasis on events that occur during DNA replication.
Chromosomes are highly dynamic structures. They undergo massive reorganization to enable DNA replication and chromosome segregation to occur. This is under the control of the DNA topoisomerases, and three related and interacting Structural Maintenance of Chromosomes(SMC) complexes known as cohesin, condensin and the Smc5/6 complex. Defects in the processes controlled by these enzymes are a potent inducer of chromosome segregation defects leading to changes in chromosome number (aneuploidy). Their function during DNA replication appears to be particularly important, where they control recombination to ensure a complete round of replication by overcoming obstacles that block polymerases, which is then followed by chromosome reorganization in preparation for mitosis. With the importance of replication fidelity, cells have back-up mechanisms controlled by a multi-BRCT domain protein (Brc1/PTIP) and the post-replication repair (PRR) machinery. We are focusing our efforts to understanding how these various genome integrity determinants are integrated in time and space to ensure accurate replication and division of the genome.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.O'Connell did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.